MedTrace Logo

Infections Associated With the Use of Alemtuzumab

NCT01315457 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 182

Last updated 2012-05-24

No results posted yet for this study

Summary

The aim of this study is to propose infection prophylaxis from Asian multinational retrospective analysis of infectious complications in patients who were treated with alemtuzumab

Conditions

  • Patients Treated With Alemtuzumab

Sponsors & Collaborators

  • National Taiwan University Hospital

    collaborator OTHER

  • Dr Cipto Mangunkusumo General Hospital

    collaborator OTHER

  • Asan Medical Center

    collaborator OTHER

  • Soon Chun Hyang University

    collaborator OTHER

  • Chonnam National University

    collaborator OTHER

  • Chonbuk National University

    collaborator OTHER

  • Chulalongkorn University

    collaborator OTHER

  • Queen Mary Hospital, Hong Kong

    collaborator OTHER

  • Yonsei University

    collaborator OTHER

  • Kyungpook National University Hospital

    collaborator OTHER

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Won Seog Kim, MD, PhD · Samsung Medical Center

Eligibility

Min Age
15 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • China
  • Indonesia
  • South Korea
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01315457 on ClinicalTrials.gov